Two groups of GSD type 1 have been recognized. GSD type la patients show an absence of glucose-6-phosphatase activity (EC. 3.1.3.9) in liver specimens. Patients with GSD type Ib have no enzyme defect in vitro, but the clinical findings are relatively indistinguishable from those of GSD type la (21, 22) . The accumulation of hepatic glycogen and the result of glucose test using a double isotope technique (19) in GSD type Ib patients suggest that the glucose-6-phosphatase is not functional in vivo. The fundamental defect in this was not understood for years.
In 1978 we reported that a basic defect in GSD type Ib was located in the G-6-P transport system of the microsomal membrane, based on the findings that the glucose-6-phosphatase activity was highly latent in the fresh liver homogenates (11, 14) . phosphatase activity in these patients can be explained as a result of freezing the tissue, which causes disruption of the microsomal membrane (I I, 14) .
Hepatic glucose-6-phosphatase is part of a multicomponent system of the endoplasmic reticulum. In 1975 Arion et al. (3) postulated that at least two components of the endoplasmic reticulum participate in the process of G-6-P hydrolysis: (1) a G-6-P specific translocase that shuttles G-6-P across the membrane and (2) a relatively nonspecific phosphohydrolase, phosphotransferase, located in the luminal surface of the membrane. Subsequently the same groups (5) reported that the glucose-6-phosphatase system consisted of an additional transport system distinct from that moving G-6-P; i.e., phosphate (Pi) translocase which mediates Pi efflux out of the cisternae of the endoplasmic reticulum. Identification of the basic defect in GSD type Ib requires assays for both G-6-P translocase and Pi translocase of intact microsomes. Recently Lange et al. (12) demonstrated that the defect is located indeed at G-6-P translocase. This finding was based on the results of activities of both G-6-P phosphohydrolase and PPi phosphohydrolase on intact microsomes from a type Ib patient.
The purpose of this report is to compare the activities of the components for the hydrolysis of G-6-P between two cases of GSD type lb. Micromethods for identification of the basic defect in GSD type 1, which can be applied to needle-biopsy specimens, are also described. CASE REPORTS Patient Y.S. is a 8-month-old boy, the second child of healthy unrelated parents. The older sister with GSD type Ib was reported previously (1 1, 14) . The patient, whose birth weight was 3.7 kg, was born after a normal pregnancy and delivery. At 2 months of age the patient was admited to our hospital because of an enlarged liver. Upon admission the patient was well-nourished. The abdomen was moderately distended, the liver was palpable 5 cm below the costal margin, and no splenomegaly was observed. Initial laboratory studies revealed a normal urinalysis, the hemoglobin 8.6 g/100 ml, and leukocyte count 5700/mm3 with a differential of 10% neutrophiles, 85% lymphocytes, 2% eosinophiles and 3% monocytes. The levels of blood glucose and lactate after a 4-h fast were 23 mg/100 ml and 39.7 mg/100 ml, respectively. Serum GOT was 68 IU/liter, GPT 34 IU/liter, triglyceride 175 mg/100 ml, and cholesterol 119 mg/100 ml. The values of the uric acid, electrolytes, urea nitrogen, total protein and alkaline phosphatase in serum were within the normal ranges. Persistent diarrhea, 10-20 times per day, developed soon after admission. Dietary and/or antibiotics treatments were not effective for diarrhea. TPN, supplying about 100 kcal/kg/day, was started 3 wk after admission.
During the TPN therapy, an improvement in the biochemical findings and a decrease in the liver size were noted. At 4 months (5) (see "Materia_ls and Methods") activity in "intact microsomes" activity in disrupted homogenates of age, the TPN was discontinued and an oral administration of a lactose free milk containing dextro-maltose and soluble starch was initiated and given every 3 h. The liver and the spleen were enlarged progressively and fasting hypoglycemia (22 mg/100 ml after 4 h of fasting), hypertriglycerides (272 mg/100 ml) and hyperuricemia (1 1.3 mg/ 100 ml) developed. During hospitalization he had multiple episodes of infection. Repeated white cell counts showed the neutropenia ranging 35-1070/mm3. The bone marrow biopsy showed a maturation arrest of myelopoiesis.
At 8 months of age, a liver needle biopsy was performed. Histologic examination showed enlarged hepatocytes with PAS positive granules. These PAS positive materials disappeared after amylase treatment. Hepatic glycogen level was 9.1 g/100 g of wet weight tissue.
Patient Y.M. is a 25-year-old woman. Hepatomegaly was first noticed at 4 years of age. Although a blood glucose determination was not done at that time, there were no symptoms suggesting hypoglycemia. Meanwhile, eruptive xanthoma appeared on both legs and hyperlipidemia was detected. At the age of 20, she was admitted to Jichi Medical School Hospital for the examination of recurrent epistaxis which continued as long as 6 h. Laboratory analysis suggested GSD type 1 and histology of liver biopsy confirmed liver GSD; however, hepatic glucose-6-phosphatase activity was normal in a frozen liver biopsy sample. A diagnosis of GSD type l b was made.
MATERIALS AND METHODS
A liver specimen was obtained by a needle biopsy from each patient. Control specimens were obtained at laparotomy from surgical patients. Informed consent was obtained from the patients or their parents. The 5% liver homogenate was prepared immediately after biopsy in 0.25 M sucrose solution containing 1 mM EDTA, pH 7.0, and centrifuged for 10 min at 1650 X g. The supernatants were divided into two portions: sodium taurocholate was added to one portion of supernatant (final concentration of 0.4 g/100 ml), and the same volume of 0.25 M sucrose was added to the other. Both supernatants were kept at O°C for 30 min. Sucrose solution (0.25 M) was added to make 2.5% homogenates immediately before the various enzyme activities were determined. The modified method of Arion et al. (2) was used to determine phosphohydrolase activity. The standard assay mixture (0.2 ml) contained 12 pmole of cacodylate buffer (pH 6.5 for G-6-P or M-6-P phosphohydrolase and pH 6.0 for PPi phosphohydrolase), 2 mg of bovine serum albumin, 60 p1 of the homogenate (equivalent to 1.5 mg of wet weight of liver) and 4 pmole of G-6-P, 4 pmole of M-6-P or 2 pmole of PPi as substrate. The mixture was incubated at 30°C in a shaking water bath for 60 min, if G-6-P or M-6-P was used as substrate and for 30 min if PPi was used as substrate. The reaction was terminated by adding 2.0 ml of 3.5% trichloroacetic acid and the tubes were then placed in an ice bath for 5 min. The released inorganic phosphate was determined on an aliquot of the trichloroacetic acid supernatant using the method of Fiske and Subbarrow (10) . Homogenate and substrate blanks were prepared with each incubation and both blank values were subtracted for the calculations of the activity. Under the assay condition, the phosphohydrolase activities using G-6-P, M-6-P, or PPi as substrate were proportional to the amount of human liver extract, up to 2.0 mg wet weight, in both untreated and taurocholate-treated (disrupted) homogenates. A linear correlation of product and incubation time was observed up to 80 min for G-6-P and M-6-P phosphohydrolase, and up to 45 min for PPi phosphohydrolase.
Untreated liver homogenates (UH) are composed of the "intact microsomes" and the small portions of the microsomes disrupted in the process of preparation. The theoretical activity for "intact microsomes" was calculated using an equation of Arion et al. (5) .
where VIM, VUH and VDH refer to the phosphohydrolase activity &mole/min/g of liver) of "intact microsomes," untreated homogenates, and fully disrupted homogenates, respectively. Fractional disruption of untreated homogenates (Ed. UH) can be calculated by dividing the M-6-P phosphohydrolase activity of untreated homogenates (VygPase) by that of fully disrupted homogenates (Vg&P"e), i.e., f.d.UH = v G"BPas" v EPme .
RESULTS
G-6-P phosphohydrolase activity. As shown in Table 1 , the activities in patients Y.S. and Y.M. were found to be markedly decreased in the untreated homogenates, whereas the enzyme activities in the disrupted preparations were higher than those in the controls. The phosphohydrolase activities of untreated homogenates are the combined activities of the "intact microsomes" (in which 100% of intrinsic enzyme is housed) and the small portions of the microsomes disrupted in the process of preparation. The latency of M-6-P phosphohydrolase activity, a good index of the intactness of the microsomal membranes (12), ranged from 82-96% for the two patients with GSD type Ib and for the controls. In order to compare the intrinsic enzyme activities among the preparations, the theoretic activities of the "intact microsomes" werk calculated (see "Materials and Methods"). The activity of the "intact microsomes" in Y.M. was 0.85 pmole/min/g of liver and none was detectable in Y.S. The latency was 100% in Y.S. and 90.7% in Y.M. On the other hand, the G-6-P phosphohydrolase activities of the patients with GSD type la were decreased in both the untreated and the disrupted homogenates, indicating a defect in the glucose-6-phosphatase itself. PPi phosphohydrolase activity. The activities of the PPi phosphohydrolase of Y.S. and Y.M. were higher than those of the controls regardless of whether or not taurocholate was present (Table 2) . Pi translocase mediates a penetration of PPi into microsomes as well as Pi efflux (5) . The data imply that the Pi translocase activity was normal in Y.S. and in Y.M.. The cases of GSD type la exhibited a markedly decreased ability to hydrolyze PPi in both the untreated and the disrupted preparations.
Kinetic studies. Kinetic analysis of G-6-P phosphohydrolase activities with preparations from Y.M. and from 4 controls were carried out. Km for G-6-P was calculated using Lineweaver-Burk plots in a range of substrate concentration between 1-100 mM (Table 3) . No significant change in Km values by taurocholate treatment from the controls were observed. When taurocholate was present, the Km value of the patient's G-6-P phosphohydrolase was also similar to those of the controls. Figure 1 shows Lineweaver-Burk plots of G-6-P phosphohydrolase activity of untreated homogenates from Y.M. and control #5. The double reciprocal plots for the control were linear, although there was some inhibition by G-6-P at the concentrations above 50 mM. On the other hand, the data for Y.M. defined a straight line only at low concentrations (1-5 mM), whereas at higher concentrations of G-6-P (10-100 mM) a substantial activation occurred. These data suggested that the untreated homogenates from Y.M. contain two components of G-6-P phosphohydrolase activity. When the data at the low substrate concentrations were extrapolated, the Km for G-6-P (low Km) was approximately 5.3 mM. This is of same order as that found in the disrupted preparations from Y.M. or the controls ( Table 3 ), suggesting that the low Km activity might be catalyzed by a component of the microsomes disrupted in the process of preparation. It is not likely that the higher activity Fig. 1 . Lineweaver-Burk plots of glucose-6-phosphate (G-6-P) phosphohydrolase activity and G-6-P concentration in untreated hornogenates from patient Y.M. ( A ) and control #5 (B). The total volume of the reagent mixture was 0.4 ml containing 24 m o l e of cacodylate buffer (pH 6.5), 4 mg of bovine serum albumin, 120 p1 of the homogenates (3 mg of wet weight liver) and concentrations of G-6-P ranging from 1.0 to 100 mM. Fig. 2 . Lineweaver-Burk plots of the high Km glucose-6-phosphate (G-6-P) phosphohydrolase activity at concentrations of 10-100 G-6-P rnM in untreated liver homogenates from patient Y.M..
at high concentrations of G-6-P was due to disruption of microsomes by high substrate concentrations, because the higher activity was not observed in Y.S.. The method of Anon et al. (4) was used in order to yield the kinetic characteristics of higher Km activity, i.e., the initial rates of the high Km activity were calculated by subtracting the contribution of the low Km component at concentrations of G-6-P between 10-100 mM from the observed rate of the hydrolysis catalyzed by the untreated preparations. In the double reciprocal plots, the calculated data points were linear (Fig. 2) . We assume that the untreated homogenates of Y.M. contain two G-6-P phosphohydrolase activities of markedly different Km and that the high Km activity is catalyzed by the glucose-6-phosphatase housed in the intact microsomes. The high Km was approximately 100 mM, this value was approximately 16 times higher than that of the controls.
D I S C U S S I O N
In 1978 we suggested that the primary lesion of GSD type l b exists in the G-6-P transport system of the microsomal membrane (11, 14) . Since then, there have been several reports in which a defect of the G-6-P transport system was confirmed (7, 9, 12, 20) . We observed three patients with GSD type l b including two siblings. These patients showed a wide range of the clinical findings. The clinical symptoms in the siblings were severe compared to most patients with GSD type l b reported in the literature (6-9, 16, 19, 21, 22) , indicating an early onset and rapid development of hypoglycemia. The patients had neutropenia (15) , which was common in cases of GSD type l b (1, 6, 7, 13, 17, 18) . On the other hand, the adult patient (Y.M.) had mild clinical symptoms; she did not have clinical symptoms of hypoglycemia, neutropenia and episodes of recurrent infections.
The G-6-P translocase can be regarded as the locus of the functional defect in the glucose-6-phosphatase in our patients because the G-6-P phosphohydrolase activities of "intact microsomes" were markedly decreased, whereas the PPi phosphohydrolase activities of "intact microsomes" were greater than those of the controls. The extent of residual activities of G-6-P translocase was different in the patients. One of siblings (Y.S.) revealed no detectable activity G-6-P translocase. The other patient had a markedly low activity (11, 14) because the latency of G-6-P phosphohydrolase activity was 92.3% without a correction based on the latency of M-6-P phosphohydrolase. The defect of G-6-P translocase was found to be partial in the adult patient (Y.M.). The clinical symptoms and enzymatic studies in the three patients suggest that the clinical severity of this disorder depends on the level of the residual activity of the G-6-P translocase.
The G-6-P phosphohydrolase in the untreated preparations from Y.M. has an apparent high Km, which is 16 times higher than those of controls. Because the high Km disappeared after treatment with detergent, the apparent high Km might reflect the Krn for the G-6-P translocase, the action of which precedes hydrolysis. The kinetic studies suggest that the deficiency in the G-6-P translocase activity in Y.M. was caused by structural abnormality of the enzyme.
The identification of the locus of the defect in the variants of GSD type 1 requires an assay for both the G-6-P and the PPi phosphohydrolase using both untreated and disrupted preparations of microsomes. The determination of M-6-P phosphohydrolase activity is also essential in order to calculate the phosphohydrolase activities for the "intact microsomes." Correcting the activity of the "intact microsomes" makes it possible to compare the function of glucose-6-phosphatase located in intact microsomes among patients. This systematic approach to the glucose-6-phosphatase system has so far been performed only in a patient with GSD type l b by Lange et al. (12) , who used liver microsomes prepared from fresh liver tissue. From the technical point of view, the determination of the enzyme activities clinically requires the use of methods which can be applied to small amounts of crude liver extracts. Our method requires only 15 mg of tissues, obtainable by needle biopsy, for the measurement of all the three phosphohydrolase activities in both the untreated and the disrupted preparations.
